SHSevda Hassan

Sevda Hassan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sevda Hassan has a total of 89 co-authors. Here are the top co-authors by number of shared publications:

  • Paul Brookes

    Histocompatibility and Immunogenetics, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK

    3 shared publications
  • Akhil Kapur

    Renal and Cardiac Directorate, Barts and the London National Health Service Trust, London, England; William Harvey Research Institute, Queen Mary and Westfield University, London, England; National Institute for Health Research Cardiovascular Biomedical Research Unit, London Chest Hospital, London, England

    2 shared publications
  • Andrew Wragg

    Renal and Cardiac Directorate, Barts and the London National Health Service Trust, London, England; National Institute for Health Research Cardiovascular Biomedical Research Unit, London Chest Hospital, London, England

    2 shared publications
  • Dan A. Jones

    Renal and Cardiac Directorate, Barts and the London National Health Service Trust, London, England; William Harvey Research Institute, Queen Mary and Westfield University, London, England; National Institute for Health Research Cardiovascular Biomedical Research Unit, London Chest Hospital, London, England

    2 shared publications
  • David Taube

    Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, UK

    2 shared publications
  • Eva Santos-Nunez

    Histocompatibility and Immunogenetics, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK

    2 shared publications

Latest Publications

  • Open Access

    Donor-specific antibodies detected by single antigen beads alone can help risk stratify patients undergoing retransplantation across a repeat HLA mismatch

    by Gaetano Lucisano, Srivathsan Thiruvengadam, Sevda Hassan, Alexander Gueret-Wardle, Paul Brookes, Eva Santos-Nunez, Michelle Willicombe


  • Open Access

    Allosensitization after transplant failure: the role of graft nephrectomy and immunosuppression – a retrospective study

    by Gaetano Lucisano, Paul Brookes, Eva Santos‐Nunez, Nicola Firmin, Nicola Gunby, Sevda Hassan, Alexander Gueret‐Wardle, Paul Herbert, Vassilios Papalois, Michelle Willicombe, et al.

    There are conflicting data about the role of transplant nephrectomy and immunosuppression withdrawal on the development of allosensitization and the impact on re-transplantation. We divided 109 first graft recipients into two groups according to whether they underwent nephrectomy (NX+, n = 61) or their graft was left in situ (NX−, n = 48). Sera were assessed for HLA-A/B/Cw/DR/DQ antibodies at the time of NX/transplant failure and after 3, 6, 12, 24 months. The NX+ group showed a higher rate of donor specific antibody (DSA) and non-DSA human leukocyte antigen (HLA) antibody production at all the time points. Multivariable analysis showed that nephrectomy was a strong, independent risk factor for the development of DSAs after 12 and 24 months (P = 0.005 and 0.008). In the NX− group, low tacrolimus levels correlated with DSA formation (AUC 0.817, P = 0.002; best cut-off level 2.9 ng/ml). Analysis with a standardized pool of UK donors showed a more difficult grade of HLA matchability following nephrectomy compared with the NX− group. Nephrectomy is followed by the long-term production of DSA and non-DSA HLA antibodies and negatively impacts on the chances of finding a HLA-compatible kidney. Tacrolimus levels ≥3 ng/ml are protective against the development of allosensitization and could facilitate re-transplantation in the NX− group.


  • Open Access

    Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post–renal transplantation

    by Sevda Hassan, Fiona Regan, Colin Brown, Andrea Harmer, Nicky Anderson, Hannah Beckwith, Candice A. Roufosse, Eva Santos-Nunez, Paul Brookes, David Taube, et al.


  • Critical Appraisal of International Clinical Practice Guidelines in Kidney Transplantation Using the Appraisal of Guidelines for Research and Education II Tool

    by Katriona Jane Marie O'Donoghue, Rhiannon D. Reed, Simon R. Knight, John M. O'Callaghan, Anam A. Ayaz-Shah, Sevda Hassan, Annemarie Weissenbacher, Peter J. Morris, Liset H.M. Pengel

    Although clinical practice guidelines (CPGs) are used for the development of local protocols in kidney transplantation (Ktx), the quality of their methodology is variable. This systematic review aimed to critically appraise international CPGs in all aspects of Ktx using the Appraisal of Guidelines for Research and Evaluation II tool. Clinical Practice Guidelines in Ktx and donation published between 2010 and 2017 were identified from MEDLINE, Embase, National Guideline Clearinghouse, National Health Service and National Institute for Health and Care Excellence Evidence Searches, and the websites of transplant societies. Using Appraisal of Guidelines for Research and Evaluation II, 3 appraisers assessed the quality of CPGs. Interrater reliability was measured using the intraclass correlation coefficient (ICC). Searches identified 3168 records, and 115 CPGs were included. The highest scoring Appraisal of Guidelines for Research and Evaluation II domain was “scope and purpose” (80%; range, 30%-100%), followed by “clarity of presentation” (77%; range, 43%-98%), “editorial independence” (52%; range, 0%-94%), “rigor of development” (47%; range 6%-97%) and “stakeholder involvement” (41%; range, 11%-85%). The poorest scoring domain was “applicability” (31%; range, 3%-74%). Most CPGs were recommended for future use either with (63%) or without (18%) modifications. A small number (14%) were not recommended for future use or reviewers (5%) did not agree on recommending the CPG. The overall mean CPG quality score was 4 of 7 (range, 2-7). The mean ICC of 0.74 indicated substantial agreement between reviewers. The quality of international CPGs in Ktx was variable, and most CPGs lacked key aspects of methodological robustness and transparency. Improvements in methodology, patient involvement, and strategies for implementation are required.


  • The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry

    by Sevda Hassan, John-Paul Westwood, Debra Ellis, Chris Laing, Siobhan Mc Guckin, Sylvia Benjamin, Marie Scully

    Thrombotic microangiopathies (TMAs) are frequently difficult to differentiate clinically, and measurement of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) remains vital in thrombotic thrombocytopenic purpura (TTP) diagnosis. We retrospectively reviewed cases referred for ADAMTS13 testing, using UK TTP Registry screening data. Of a total 810 cases, 350 were confirmed as TTP. The 460 non-TTP cases comprised secondary TMAs (24·57%) and haemolytic uraemic syndrome (HUS) (27·17% aHUS, 2·83% Shiga-like toxin-producing E. coli [STEC]-HUS); the remainder were TMAs with no clear association, not TMAs, or had no confirmed diagnosis. ADAMTS13 levels were significantly lower in TTP than STEC-HUS, aHUS and other TMAs. TTP patients had significantly lower platelet count (15 × 10(9) /l; range 0-96) than aHUS (57 × 10(9) /l; range 13-145, P < 0·0001) or STEC-HUS (35 × 10(9) /l; range 14-106, P < 0·0001); they also had lower creatinine levels (92 μmol/l; range 43-374) than aHUS (255 μmol/l; range 23-941, P < 0·0001) and STEC-HUS (324 μmol/l; range 117-639, P < 0·0001). However, 12/34 (35·3%) aHUS patients had a platelet count 30 × 10(9) /l; 23/150 (15·3%) of TTP patients had a creatinine level >150 μmol/l. This study highlights the wide variety of TMA presentations, and confirms the utility of ADAMTS13 testing in TTP diagnosis.


  • The impact of acute kidney injury on midterm outcomes after coronary artery bypass graft surgery: A matched propensity score analysis

    by Sean Gallagher, Dan A. Jones, Matthew J. Lovell, Sevda Hassan, Andrew Wragg, Akhil Kapur, Rakesh Uppal, Muhammad M. Yaqoob


  • Open Access

    Impact of diabetes mellitus and renal insufficiency on 5-year mortality following coronary artery bypass graft surgery: a cohort study of 4869 UK patients

    by Sean Gallagher, Akhil Kapur, Matthew J. Lovell, Dan A. Jones, Amy Kirkwood, Sevda Hassan, R. Andrew Archbold, Andrew Wragg, Rakesh Uppal, Muhammad M. Yaqoob

    Diabetes mellitus (DM) and renal impairment (RI) are both independent predictors of mortality after coronary artery bypass graft surgery (CABG). The two conditions often coexist, yet the impact on long-term prognosis after CABG of each factor relative to the other and the two in combination is uncertain. We undertook a prospective cohort study of 4869 patients who underwent CABG between 2003 and 2007. The cohort was divided into four groups according to preoperative diabetic status and renal function: patients without either DM or RI (reference group), patients with DM alone, patients with RI alone and patients with both DM and RI. Clinical outcomes were compared between groups. Patients receiving renal replacement therapy were excluded. The primary outcome was 5-year all-cause mortality. The crude 5-year all-cause mortality rate was 9.0% for patients in the reference group, 11.1% for patients with DM alone, 20.3% for patients with RI alone and 28.5% for patients with both DM and RI (P < 0.0001). Five-year survival adjusted for potential confounding factors was significantly worse for patients with DM (hazard ratio (HR) 1.30; 95% confidence interval (CI) 1.06–1.59), patients with RI (HR 1.32; 95% CI 1.08–1.61) and patients with both DM and RI (HR 2.04; 95% CI 1.65–2.53) when compared with patients with neither condition. Preoperative DM and RI were important predictors of 5-year mortality after CABG. Patients with RI alone had a higher mortality rate than patients with DM alone, but this difference was largely accounted for by age and other comorbidities. The combination of DM and RI doubled the 5-year mortality rate after CABG independently of potential confounding factors.


  • AIP, a Protein Mutated in Familial Acromegaly, Plays a Role in the Regulation of Cell Proliferation and Shows Cell-Type Specific Subcellular Localisation

    by C.A. Leontiou, M. Gueorguiev, S. Hassan, J. van der Spuy, F. Lolli, M. Stolbrink, H.C. Christian, J. Wray, D. Bishop-Bailey, D.M. Berney, et al.

  • Open Access

    The Role of the Aryl Hydrocarbon Receptor-Interacting Protein Gene in Familial and Sporadic Pituitary Adenomas

    by Chrysanthia A. Leontiou, Maria Gueorguiev, Jacqueline van der Spuy, Richard Quinton, Francesca Lolli, Sevda Hassan, Harvinder S. Chahal, Susana C. Igreja, Suzanne Jordan, Janice Rowe, et al.

    Context: Mutations have been identified in the aryl hydrocarbon receptor-interacting protein (AIP) gene in familial isolated pituitary adenomas (FIPA). It is not clear, however, how this molecular chaperone is involved in tumorigenesis. Objective: AIP sequence changes and expression were studied in FIPA and sporadic adenomas. The function of normal and mutated AIP molecules was studied on cell proliferation and protein-protein interaction. Cellular and ultrastructural AIP localization was determined in pituitary cells. Patients: Twenty-six FIPA kindreds and 85 sporadic pituitary adenoma patients were included in the study. Results: Nine families harbored AIP mutations. Overexpression of wild-type AIP in TIG3 and HEK293 human fibroblast and GH3 pituitary cell lines dramatically reduced cell proliferation, whereas mutant AIP lost this ability. All the mutations led to a disruption of the protein-protein interaction between AIP and phosphodiesterase-4A5. In normal pituitary, AIP colocalizes exclusively with GH and prolactin, and it is found in association with the secretory vesicle, as shown by double-immunofluorescence and electron microscopy staining. In sporadic pituitary adenomas, however, AIP is expressed in all tumor types. In addition, whereas AIP is expressed in the secretory vesicle in GH-secreting tumors, similar to normal GH-secreting cells, in lactotroph, corticotroph, and nonfunctioning adenomas, it is localized to the cytoplasm and not in the secretory vesicles. Conclusions: Our functional evaluation of AIP mutations is consistent with a tumor-suppressor role for AIP and its involvement in familial acromegaly. The abnormal expression and subcellular localization of AIP in sporadic pituitary adenomas indicate deranged regulation of this protein during tumorigenesis.